---
title: "China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC"
pubDate: "2025-06-30"
category: "business"
image: "https://cdn.sanity.io/images/0vv8moc6/onclive/29d40301d38489d149b41ebae8350267d67f754b-1920x1080.jpg?fit=crop&auto=format"
slug: "china-nmpa-approves-savolitinib-plus-osimertinib-for-egfr-mutant-met-amplified-n"
source: "OncLive"
lang: "en"
---

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

EGFR-Mutant NSCLC | Image by
Ashling Wahner & MJH Life Sciences
Using AI
China’s National Medical Products Administration (NMPA) has approved the combination of savolitinib (Orpathys) and osimertinib (Tagrisso) for the treatment of patients with loca... [6086 chars]

[Kaynak](https://www.onclive.com/view/china-nmpa-approves-savolitinib-plus-osimertinib-for-egfr-mutant-met-amplified-nsclc)
